The Medical segment of BD (Becton, Dickinson and Co.) focuses on solutions to reduce the spread of infection, enhance diabetes treatment, advance drug delivery, improve surgical procedures and more. And come July 1, it will have a new leader.
The Franklin Lakes medical tech company announced June 7 it appointed Simon Campion as executive vice president and president of the Medical segment. He will take over from Alberto Mas, who announced his retirement from the company in March.
Campion, who will report to Chairman, CEO and President Tom Polen, will be responsible for the global strategic, operational and commercial performance of the segment’s portfolio, and will be accountable for delivering its agenda as it relates to BD’s 2025 strategy.
Campion has served as executive vice president and president of BD’s Interventional segment since September 2018. The company said he will continue to lead this unit until a successor is named.
In April 2017, BD announced it acquired medical tech company C.R. Bard Inc. for $24 billion. Campion had joined that company in 2008, serving in several leadership positions in the U.S. and Europe. After the acquisition, Campion, serving as president of the BD’s Surgery business unit, integrated the Bard and BD product platforms, the company said. Prior to Bard, he held marketing and R&D roles at Cook Medical and Boston Scientific.
Polen
“Simon is a proven business leader with excellent strategic and operational skills and deep global experience,” Polen said in a statement. “Since joining BD from the Bard acquisition, Simon has been integral in the integration and growth of the legacy Bard businesses across the Interventional segment and is well positioned to lead BD’s largest segment.”
Campion earned a doctorate in mechanical engineering from the University of Limerick in Ireland and an MBA from The Open University in the United Kingdom.
